Limited data support the use of propionyl-L-carnitine for treatment of intermittent claudication in patients with peripheral artery disease, and data do not support its use in the treatment of congestive heart failure
Permanent genetic access to transiently active neurons via TRAP: targeted recombination in active populations
Still, it may be relevant to perform pilot studies to address whether the therapy will benefit selected HFrEF cohorts with obesity.
The benefits of glutathione and vitamin ingredients are all packed into one film
This is why short-half-life secretagogues are favored for studying physiological pulsatile dynamics
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited